Fig. 5

PRRX2 is expressed at higher levels in GBM and is correlated with poor patient survival. a, c, e, g The expression of PRRX2 in different WHO grades (a), IDH mutant status (c), 1p19q codeletion status (e) and three molecular subtypes (g) in CGGA GBM datasets. b, d, f, h The expression of PRRX2 in different WHO grades (b), IDH mutant status (d), 1p19q codeletion status (f) and three molecular subtypes (g) in TCGA GBM datasets. i-k The prognostic significance of PRRX2 was confirmed in the CGGA (i), TGGA (j) databases and our 70 glioma patients (k) according to Kaplan–Meier survival analysis. l: qPCR assays showed the mRNA expression of PRRX2 in GBM and NBT tissues (left) and different WHO-grade glioma tissues (right). m, n Western blotting (m) and immunohistochemistry assays (n) showed PRRX2 expression in different WHO-grade glioma tissues. Scale bar = 40 μm. All data are expressed as the mean ± SD (three independent experiments). *p < 0.05; **p < 0.01; ***p < 0.001